Mode
Text Size
Log in / Sign up

Paracetamol or ibuprofen treatment outcomes in preterm infants with patent ductus arteriosus: a retrospective cohort analysis.

Paracetamol or ibuprofen treatment outcomes in preterm infants with patent ductus arteriosus: a retr…
Photo by Navy Medicine / Unsplash
Key Takeaway
Note associations between treatment response and mortality in this retrospective cohort study of preterm infants.

This retrospective cohort study was conducted in the neonatal intensive care unit of a tertiary care center. The population consisted of 60 preterm infants admitted with echocardiographically confirmed patent ductus arteriosus. The overall PDA incidence was 2.8% based on 60/2154 cases. Patients received pharmacological treatment with intravenous paracetamol or ibuprofen. Clinical improvement after first-line treatment was reported in 77% of the cohort. Ductal closure after first-line treatment occurred in 83.3% of patients. Most follow-up assessments were completed within 3 days. Predictors of successful closure included gestational age of 28 weeks or greater, with an OR = 5.9 and 95% CI: 1.7-20.2. Antenatal corticosteroid exposure showed an OR = 1.2 with 95% CI: 1.0-1.6. Overall mortality was 35%. Infants under 28 weeks had increased mortality with an OR = 5.0 and 95% CI: 2.4-10.3. Clinical improvement and echocardiographic closure were associated with reduced mortality, with OR = 3.7 and OR = 4.5 respectively. Safety data regarding adverse events were not reported. Serious adverse events were not reported. Discontinuations were not reported. Tolerability was not reported. The observational design limits causal inference. Systematic echocardiographic screening in high-risk neonates should be considered. This study was published as an abstract. Funding or conflicts were not reported.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundPatent ductus arteriosus (PDA) is a common and potentially serious cardiovascular condition in preterm infants, particularly those with low gestational age and birth weight. Its management remains controversial due to variability in screening, diagnostic criteria, and treatment strategies. This study aimed to evaluate risk factors, outcomes, and management strategies for PDA in preterm infants, and to identify predictors of clinical and echocardiographic response to therapy. MethodsWe conducted a retrospective cohort study over a 4-year period (2016-2019) in the neonatal intensive care unit (NICU) of a tertiary care center. All consecutive preterm infants admitted during the study period were eligible. Infants with echocardiographically confirmed PDA who received pharmacological treatment with intravenous paracetamol or ibuprofen were included in the analysis. Missing data were minimal and handled using available-case analysis. Statistical analyses included descriptive statistics, Pearsons chi-square test, and multivariable logistic regression. ResultsAmong 2154 preterm infants admitted to the NICU, 60 were diagnosed with PDA (incidence : 2.8%). The mean gestational age was 29 {+/-} 2.6 weeks, and the median birth weight was 1200 g. Respiratory distress occurred in 95% of cases, mainly due to hyaline membrane disease (86.7%). PDA was symptomatic in 80% of infants. First-line treatment resulted in clinical improvement in 77% and ductal closure in 83.3% of cases, most within 3 days. Predictors of successful closure included gestational age [&ge;] 28 weeks (OR = 5.9; 95% CI : 1.7-20.2) and antenatal corticosteroid exposure (OR = 1.2; 95% CI : 1.0-1.6). Overall mortality was 35% and was significantly higher in infants < 28 weeks (OR = 5.0; 95% CI : 2.4-10.3). Clinical improvement (OR = 3.7) and echocardiographic closure (OR = 4.5) after first-line treatment were associated with reduced mortality. ConclusionsPDA in preterm infants is associated with substantial morbidity and mortality, particularly in those born before 28 weeks of gestation. Early diagnosis, antenatal corticosteroid exposure, and timely pharmacological treatment may improve outcomes. Systematic echocardiographic screening in high-risk neonates should be considered.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.